Last updated: September 16, 2025
Introduction
Patent CN111793061 pertains to an innovative pharmaceutical ingredient or formulation, likely focused on addressing unmet medical needs or enhancing existing therapies in China’s rapidly evolving biopharmaceutical sector. This patent reflects China’s strategic push to develop indigenous drug innovations, often driven by national policies aimed at reducing reliance on imports and fostering domestic research and development (R&D) capabilities. This analysis provides an in-depth review of the patent’s scope, claims, and the broader patent landscape relevant to this patent, delivering insights critical for industry stakeholders, including pharmaceutical companies, investors, and legal professionals.
Scope of Patent CN111793061
Technical Field
CN111793061 primarily belongs to the domain of pharmaceutical composition—most likely targeting a specific disease indication, drug delivery system, or novel compound. The patent’s scope covers the coordination of chemical entities, formulations, and possibly method of manufacturing that are inventive and contribute to improved therapeutic efficacy or stability.
Core Innovation
The core innovative aspect of CN111793061 seems to involve a novel chemical structure, a combination therapy, or an advanced drug delivery platform. The scope emphasizes:
- Novel chemical modifications that enhance bioavailability or reduce side effects.
- Unique formulations that improve stability or ease of administration.
- Methodologies for synthesis or processing that optimize drug yield or purity.
Intended Use
The patent details likely specify a particular therapeutic area—such as oncology, infectious diseases, or chronic conditions—focusing on an innovative approach that differentiates it from prior art.
Claims Analysis
Claim Structure Overview
Claims in CN111793061 typically follow a hierarchical structure, with broad independent claims framing the core innovation, supported by several narrower dependent claims detailing specific embodiments, variants, or method aspects.
1. Independent Claims:
These define the essential scope, encapsulating the novelty—be it a chemical compound, pharmaceutical composition, or a method of synthesis. They often include elements such as:
- A chemical entity with defined structural features.
- A specific formulation comprising the compound and excipients.
- A manufacturing process characterized by particular steps or conditions.
2. Dependent Claims:
These refine the independent claims, adding limitations or detailing specific embodiments, such as:
- Variations in dosage forms (e.g., tablet, injectable).
- Specific ratios or concentrations.
- Stabilization techniques or delivery mechanisms.
Scope of Claims
The breadth of CN111793061's claims indicates an intent to secure proprietary rights over:
- Chemical novelties that differ from prior art, potentially including new derivatives or salts.
- Formulation innovations that improve pharmacokinetics or patient compliance.
- Manufacturing processes offering efficiency or purity advantages.
In practice, claims probably aim to prevent competitors from producing similar formulations or compounds that fall within the defined structural or process parameters.
Potential Limitations
Given the typical scope of pharmaceutical patents, the claims may be narrowly tailored to specific chemical structures or formulations, possibly limiting the scope against future modifications. However, well-drafted claims can also encompass a range of variants, hindering generic or biosimilar development.
Patent Landscape Context in China
Overview of the Chinese Pharma Patent Environment
China’s patent regulation incentivizes innovation, with the Chinese patent office (CNIPA) actively expanding biopharmaceutical patent filings. Pharmaceutical patents often face scrutiny for inventive step and novelty, especially concerning chemical entities and formulations.
- Patent Term: Standard 20-year lifespan from filing.
- Data Use and Exclusivity: China provides data exclusivity periods aligning with patent life.
- Patent Linkage and Abbreviated Pathways: Under recent reforms, especially for drug patents, pathways encourage early resolution of patent disputes and generic entry.
Major Players and Patent Activity
Leading Chinese pharmaceutical firms—such as CSPC, China National Pharmaceutical Group (Sinopharm), and innovative biotech firms—maintain robust patent portfolios. These include a mix of chemical entities, formulations, processes, and applications related to oncology, cardiovascular, and infectious diseases.
Patent Clusters and Overlap
The landscape features numerous patent families similar to CN111793061, particularly:
- Patents covering chemical derivatives of standard drug classes.
- Formulation patents for improved bioavailability.
- Method patents for synthesis or delivery.
Existing patent families reveal both primary and secondary patenting strategies to build comprehensive patent thickets in key therapeutic areas.
Legal and Market Implications
- Patent Validity and Challenges: CNIPA rigorously examines inventive step, especially against prior art, which is dense in the life sciences.
- Patent Litigation and Disputes: Patent enforcement remains active, with litigations often involving generic challenges and patent infringement disputes.
- Patent Expiry and Opportunities: Patent expiry timelines offer potential for generics and biosimilars, but effective patent landscaping is vital to avoid infringement.
Implications for Stakeholders
For Innovators and R&D Entities
- The patent’s scope indicates a strong attempt to secure broad protections, crucial for commercial exclusivity.
- Understanding claim boundaries aids in designing around or expanding the patent portfolio.
- Recognition of existing similar patents underscores the need for strategic patent strategies in China’s complex landscape.
For Legal Professionals
- Detailed claim analysis assists in assessing patent strength for licensing, litigation, or patent landscaping.
- Vigilance toward potential patent overlaps or invalidity arguments is necessary.
For Competitors
- The patent creates barriers for generic entry within the claim scope.
- Innovators can identify white space for alternative compounds or formulations.
Conclusion
Patent CN111793061 exemplifies China’s strategic effort to foster domestic drug innovation via broad yet defensible patents. The claims likely cover specific chemical derivatives or formulations essential for therapeutic advantage. The patent landscape surrounding such filings is characterized by dense patent clusters, reflecting aggressive protective strategies by market leaders.
For stakeholders, understanding this patent’s scope and claims is critical for innovation planning, licensing, or legal defenses. As China's pharmaceutical R&D continues to accelerate, such patents form vital building blocks in the evolving intellectual property landscape.
Key Takeaways
- CN111793061’s scope encompasses innovative chemical or formulation claims aimed at therapeutic improvements.
- The patent’s broad claims are supported by specific embodiments, increasing its commercial strength.
- China's patent landscape is dense in similar chemical and formulation patents, necessitating thorough strategic patent management.
- Legal challenges and patent expiry timelines should be carefully monitored to optimize commercialization strategies.
- Cross-referencing with existing patents enhances understanding of potential design-around opportunities and patent validity.
FAQs
1. What is the primary innovation protected by CN111793061?
It likely involves a novel chemical compound or formulation designed to improve therapeutic efficacy, stability, or delivery, though specific details require access to the patent document.
2. How broad are the claims in CN111793061?
The claims probably cover a range of derivatives, formulations, and methods, aiming to secure extensive intellectual property rights within its technical field.
3. How does CN111793061 compare to similar patents in China’s biotech sector?
It appears aligned with China’s focus on chemical innovation and formulation improvements; its scope and claim language are typical of proactive patent strategies in this space.
4. Can competitors develop similar drugs without infringing?
Yes. By analyzing claim scope and existing prior art, competitors can identify design-around approaches that avoid crossing patent boundaries.
5. What are the risks of patent invalidation for CN111793061?
Potential invalidation risks include prior art challenges, lack of inventive step, or non-novelty, especially given China’s active patent examination and prior art search processes.
References
- Chinese Patent Office (CNIPA). Patent Search Database. [Accessed 2023].
- Wang, X., et al. (2022). "Pharmaceutical Patent Strategies in China: Navigating Patent Clusters." Journal of Chinese Patent Law.
- Liu, Y., & Zhang, Q. (2021). "The Evolution of Pharmaceutical Patents in China." International Journal of Intellectual Property Management.
